Compare BTAI & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTAI | NDLS |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 68.7M |
| IPO Year | 2018 | 2013 |
| Metric | BTAI | NDLS |
|---|---|---|
| Price | $0.07 | $14.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 9.6M | 26.2K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.63 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $495,089,000.00 |
| Revenue This Year | $197.82 | N/A |
| Revenue Next Year | $910.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.37 |
| 52 Week Low | $0.07 | $0.47 |
| 52 Week High | $3.41 | $19.00 |
| Indicator | BTAI | NDLS |
|---|---|---|
| Relative Strength Index (RSI) | 19.82 | 45.38 |
| Support Level | N/A | $12.83 |
| Resistance Level | $1.22 | $16.10 |
| Average True Range (ATR) | 0.06 | 0.85 |
| MACD | -0.07 | -0.14 |
| Stochastic Oscillator | 0.57 | 26.48 |
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.